AstraZeneca, Merck Sue to Stop Copies of Cancer Drug Lynparza

AstraZeneca Plc and partner Merck & Co. filed lawsuits alleging that copies of Lynparza proposed by Sandoz Group AG and Natco Pharma Ltd. infringe two patents issued in the past week for the blockbuster cancer drug.

The generic versions infringe US Patent Nos. 11,970,530 and 11,975,001, issued on April 30 and Tuesday, respectively, according to separate complaints filed against Natco and Sandoz on Tuesday in the US District Court for the District of New Jersey.

• The complaints expand the disputes involving four other patents for Lynparza. Those cases, later consolidated and pending in the same district court, now assert ...